CD274 and non-small cell lung carcinoma: However, a systematic review of published data of trials utilizing PD-1 (nivolumab and pembrolizumab) and PD-L1 inhibitors (atezolizumab, durvalumab, and avelumab) in NSCLC patients found similar toxicity between PD-1 and PD-L1 inhibitors [45].